Thamyongkit Sorawut, Bachabi Malick, Thompson John M, Shafiq Babar, Hasenboehler Erik A
1Department of Orthopaedic Surgery, The Johns Hopkins University/Johns Hopkins Bayview Medical Center, 4940 Eastern Ave., Baltimore, MD 21224 USA.
2Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchatewi, Bangkok, 10400 Thailand.
Patient Saf Surg. 2018 Jun 7;12:10. doi: 10.1186/s13037-018-0156-2. eCollection 2018.
The increasing financial burden of orthopaedic implants on our health care system has prompted cost-control measures, such as implant reprocessing. The purpose of this study was to describe the current usage by orthopaedic trauma surgeons of reprocessed external fixators (EFs) for treatment of complex fractures.
A 16-question survey about use and perceptions of reprocessed EFs was distributed to 894 Orthopaedic Trauma Association members between August 2016 and June 2017 using a web-based survey system.
The authors received 243 responses (27%). Thirty-seven percent of respondents reported using reprocessed EFs. Nonprofit hospitals used reprocessed EFs more commonly than did for-profit hospitals (41% vs 15%, = .0004). Eighty-seven percent of respondents believed reprocessing could be cost-effective. The most common reason (32%) for not using reprocessed EFs was coordination/logistics of reprocessing. Concern about litigation was also reported as a main reason for not using (20%) or having recently stopped using (21%) reprocessed EFs.
Many orthopaedic traumatologists are interested in the reprocessing of EF components but few have reprocessing systems in place at their institutions. A major barrier to implementation is concern about litigation, which is likely unwarranted on the basis of Food and Drug Administration approval and a lack of previous litigation. Reprocessing by the original device manufacturers has yielded substantial savings at our institution and is an example of the cost savings that can be expected when implementing an EF reprocessing system.
骨科植入物给我们的医疗保健系统带来的经济负担日益加重,这促使人们采取成本控制措施,如植入物再处理。本研究的目的是描述骨科创伤外科医生目前对再处理外固定器(EFs)治疗复杂骨折的使用情况。
2016年8月至2017年6月期间,通过基于网络的调查系统向894名骨科创伤协会成员发放了一份关于再处理EFs的使用和看法的16个问题的调查问卷。
作者收到了243份回复(27%)。37%的受访者报告使用过再处理的EFs。非营利性医院比营利性医院更常用再处理的EFs(41%对15%,P = 0.0004)。87%的受访者认为再处理可能具有成本效益。不使用再处理EFs的最常见原因(32%)是再处理的协调/后勤问题。对诉讼的担忧也被报告为不使用(20%)或最近停止使用(21%)再处理EFs的主要原因。
许多骨科创伤学家对EF组件的再处理感兴趣,但他们所在机构中很少有再处理系统。实施的一个主要障碍是对诉讼的担忧,基于美国食品药品监督管理局的批准和以往缺乏诉讼情况来看,这种担忧可能是没有必要的。在我们机构,由原设备制造商进行再处理已节省了大量资金,这是实施EF再处理系统有望实现成本节约的一个例子。